Loading…
NewGenIvf Group Limited is projected to decline to $1.23 by 2027, a -6% move from its current price of $1.31. NIVF is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.15 | $1.31 | $1.49 | -0.10% |
| Jul 13 | $1.09 | $1.31 | $1.56 | -0.20% |
| Jul 14 | $1.05 | $1.31 | $1.63 | -0.30% |
| Jul 15 | $1.01 | $1.30 | $1.68 | -0.40% |
| Jul 16 | $0.9818 | $1.30 | $1.73 | -0.50% |
| Jul 17 | $0.9546 | $1.30 | $1.78 | -0.60% |
| Jul 18 | $0.9303 | $1.30 | $1.82 | -0.70% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9303 | $1.30 | $1.82 | -0.70% |
| Week 2 | $0.804 | $1.29 | $2.08 | -1.39% |
| Week 3 | $0.7177 | $1.28 | $2.29 | -2.08% |
| Week 4 | $0.6514 | $1.27 | $2.49 | -2.76% |
| Week 5 | $0.5976 | $1.26 | $2.68 | -3.44% |
| Week 6 | $0.5525 | $1.26 | $2.86 | -4.12% |
| Week 7 | $0.5137 | $1.25 | $3.03 | -4.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NewGenIvf Group Limited is an investment holding company that provides assisted reproductive services for fertility treatment in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company offers a broad range of fertility solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing.
It also delivers IVF treatment, surrogacy and ancillary caring services, and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. Services are provided through clinics. NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
NewGenIvf Group Limited (NIVF) is currently priced at $1.31 with a market cap of $4.48M and a market rank of 5359. The stock sits in the healthcare sector and is subject to the volatile movements typical of small-cap wellness services firms.
The forecast presents a varied path over the coming years, with 2026 avg $1.31, 2027 avg $1.23, 2028 avg $0.9878, 2029 avg $0.8453, 2030 avg $1.03, 2031 avg $1.19, 2032 avg $1.48, 2033 avg $1.46, 2034 avg $1.17, 2035 avg $1.28, 2040 avg $1.85, and 2050 avg $2.66. The range of outcomes includes negative ROIs in the late 2020s and turning positive in the 2040s, with 2040 at 40.9 and 2050 at 103.4 as notable bullish milestones.
Overall, the outlook shows mixed momentum in the near term and stronger upside potential later, with sentiment shifting toward bullish by the 2040s and beyond, though these figures are estimates and not guarantees.
A major floor 93.3% below — a decisive break under it would weaken the trend.
The nearest floor, 64.8% below — buyers have tended to step in here.
The nearest ceiling, 13.7% above — a clean break opens room to run.
A major ceiling 111.0% above — clearing it would confirm fresh momentum.
Key NIVF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NIVF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.37 | Sell | $1.25 | Buy |
| MA 10 | $0.9467 | Buy | $1.07 | Buy |
| MA 20 | $0.7998 | Buy | $0.9333 | Buy |
| MA 50 | $0.9465 | Buy | $1.29 | Buy |
| MA 100 | $1.63 | Sell | $13.30 | Sell |
| MA 200 | $19.42 | Sell | $252.46 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.62 | Neutral |
| Stoch RSI (14) | 86.34 | Sell |
| CCI (20) | 140.84 | Buy |
| Williams %R (14) | -8.75 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 115.72 | Buy |
| Bollinger %B (20,2) | 0.94 | Neutral |
| Stochastic %K (14) | 91.25 | Sell |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | 0.56 | Buy |
| Ultimate (7,14,28) | 73.85 | Sell |
| Momentum (10) | 0.80 | Buy |
| Aroon Osc (25) | 4.00 | Buy |
| Hull MA (9) | 1.56 | Sell |
| ADX (14) | 29.44 | Buy |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is bullish, supported by RSI14 at 60. The asset trades with SMA50 at $0.9821 and SMA200 at $21.12, illustrating a wide gap between short- and long-term averages.
Key support sits at $0.461, with resistance at $1.49. The 30-day price range runs from a low of $0.5295 to a high of $3.24, highlighting a broad near-term trading band and potential for volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.461 | $1.31 | $1.46 | 0% | Neutral | |
| $0.8889 | $1.23 | $1.83 | -6% | Neutral | |
| $0.6791 | $0.9947 | $1.58 | -24% | Bearish | |
| $0.5461 | $0.8427 | $1.41 | -36% | Bearish | |
| $0.6354 | $1.03 | $1.78 | -22% | Bearish | |
| $0.7061 | $1.19 | $2.14 | -9% | Neutral | |
| $0.8359 | $1.47 | $2.73 | +13% | Neutral | |
| $0.7964 | $1.46 | $2.78 | +12% | Neutral | |
| $0.6147 | $1.17 | $2.29 | -10% | Neutral | |
| $0.6419 | $1.27 | $2.55 | -3% | Neutral | |
| $0.8377 | $1.86 | $4.09 | +42% | Bullish | |
| $1.18 | $2.63 | $6.06 | +101% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.461 | $1.31 | $1.54 | +0.00% |
| August 2026 | $0.9762 | $1.18 | $1.49 | -9.69% |
| September 2026 | $0.973 | $1.20 | $1.54 | +1.08% |
| October 2026 | $0.9442 | $1.17 | $1.54 | -1.77% |
| November 2026 | $0.8644 | $1.09 | $1.45 | -7.50% |
| December 2026 | $0.8532 | $1.08 | $1.46 | -0.33% |
Click any year to see its month-by-month NIVF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NIVF price prediction for 2026 points to an average of $1.31 (low $0.461, high $1.46) — a potential gain of 0% on today's $1.31. Price action looks broadly range-bound.
In 2027, NIVF is projected to trade between $0.8889 and $1.83, averaging $1.23 — a potential decline of -6% from today's $1.31. That is -6% versus the projected 2026 average. A consolidation phase looks the most probable path here.
NewGenIvf Group Limited's 2028 outlook centres on $0.9947, within a $0.6791 to $1.58 range. That is -19% versus the projected 2027 average. That marks a -24% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2029, NIVF could reach as high as $1.41, with a base case around $0.8427 and support toward $0.5461 — roughly -36% from $1.31. Expect choppier, lower action through this leg of the cycle.
Expect NIVF to range from $0.6354 to $1.78 through 2030. The $1.03 average target implies a -22% move from current prices. That is up +22% on the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The NIVF price prediction for 2031 points to an average of $1.19 (low $0.7061, high $2.14) — a potential decline of -9% on today's $1.31. A consolidation phase looks the most probable path here.
In 2032, NIVF is projected to trade between $0.8359 and $2.73, averaging $1.47 — a potential gain of +13% from today's $1.31. That is up +23% on the projected 2031 average. Price action looks broadly range-bound.
NewGenIvf Group Limited's 2033 outlook centres on $1.46, within a $0.7964 to $2.78 range. That is -1% versus the projected 2032 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, NIVF could reach as high as $2.29, with a base case around $1.17 and support toward $0.6147 — roughly -10% from $1.31. Price action looks broadly range-bound.
Expect NIVF to range from $0.6419 to $2.55 through 2035. The $1.27 average target implies a -3% move from current prices. That is up +9% on the projected 2034 average. A consolidation phase looks the most probable path here.
The NIVF price prediction for 2040 points to an average of $1.86 (low $0.8377, high $4.09) — a potential gain of +42% on today's $1.31. Momentum favours further upside here.
In 2050, NIVF is projected to trade between $1.18 and $6.06, averaging $2.63 — a potential gain of +101% from today's $1.31. That is up +41% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NIVF today (≈ 763.358779 NIVF) could be worth
$2,010.07
+$1,010.07 (+101%) by 2050 · US Dollar
Based on the average projected NIVF price of $2.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NIVFwould be worth at today's price.
$1,000 invested in NIVF on Jul 10, 2025 (≈ 5.324814 NIVF) would be worth
$6.98
-$993.02 (-99.3%) today · 0.01× · US Dollar
Based on a NIVF entry price of $187.8 vs. today's $1.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.461 | $2,841.65 | +184.2% |
| 1 month ago | $0.537 | $2,439.48 | +143.9% |
| 3 months ago | $2.04 | $642.79 | -35.7% |
| 6 months ago | $6.96 | $188.22 | -81.2% |
| 1 year ago | $187.8 | $6.98 | -99.3% |
| All time (4.3y) ago | $29,490 | $0.04 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NIVF forecast.
Our base-case forecast reaches $2.60 around 2050.
Implied market cap at $2.60: $8.89M
The multi-year forecast shows a mixed path, with early years characterized by neutral to bearish sentiment and a shift toward bullish by the 2040s. Notably, 2026 carries a neutral stance with an average of $1.31 and ROI of 0, while 2027/2028/2029 carry neutral to bear signals and declining averages.
In 2030, the average is projected at $1.03 with a forecast ROI of -21.3. By 2040, the average rises to $1.85 with a forecast ROI of 40.9, and by 2050 the average reaches $2.66 with a forecast ROI of 103.4. Max forecasts also imply upside, with 2032 at $2.74, 2033 at $2.78, 2040 at $4.05, and 2050 at $6.13.
These are estimates, not guarantees, and should be considered in the context of market volatility and sector dynamics that can affect real outcomes.
Tap a question to reveal the answer.
2030 avg $1.03, ROI -21.3.
Forecasts show neutral in 2026 (avg $1.31, ROI 0) and later turning bullish by 2040 (avg $1.85, ROI 40.9) and 2050 (avg $2.66, ROI 103.4), but early years include bearish signals. These are estimates, not guarantees.
Yes—2032 to 2033 show modest maxes ($2.74 and $2.78), and 2040 has a max of $4.05, with 2050 at $6.13.
Current price $1.31; Market cap $4.48M.
30-day range low $0.5295, high $3.24; Sentiment: BULLISH.
NewGenIvf Group Limited Community Discussion
0Share your NewGenIvf Group Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.